B
9.35
0.35 (3.89%)
| Penutupan Terdahulu | 9.00 |
| Buka | 9.05 |
| Jumlah Dagangan | 283,027 |
| Purata Dagangan (3B) | 361,515 |
| Modal Pasaran | 335,244,608 |
| Harga / Pendapatan (P/E TTM) | 0.687 |
| Harga / Jualan (P/S) | 51.50 |
| Harga / Buku (P/B) | 1.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -1,133.43% |
| EPS Cair (TTM) | -1.98 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.29% |
| Nisbah Semasa (MRQ) | 13.68 |
| Aliran Tunai Operasi (OCF TTM) | -53.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.85 M |
| Pulangan Atas Aset (ROA TTM) | -19.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | BioAge Labs, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 3.63% |
| % Dimiliki oleh Institusi | 66.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Pivotal Bioventure Partners Investment Advisor Llc | 30 Sep 2025 | 653,374 |
| Redpoint Management, Llc | 30 Sep 2025 | 383,254 |
| Julat 52 Minggu | ||
| Median | 15.00 (60.43%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 29 Oct 2025 | 15.00 (60.43%) | Beli | 7.68 |
| 22 Oct 2025 | 10.00 (6.95%) | Beli | 6.05 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor |
| 25 Nov 2025 | Pengumuman | BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference |
| 07 Nov 2025 | Pengumuman | BioAge Labs to Present at Jefferies Global Healthcare Conference in London |
| 06 Nov 2025 | Pengumuman | BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 15 Sep 2025 | Pengumuman | HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |